Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Armodafinil adjunct to sleep restriction therapy for insomnia disorder
ACTRN12614001293651Phase 2Completed
- Sponsor
- Woolcock Institute of Medical Research
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of armodafinil in Insomnia (2 arms), sponsored by Woolcock Institute of Medical Research. Primary endpoint: Insomnia Severity Index. Started Mar 2017; status: completed.
02
Drugs
armodafinil
03
Conditions
Insomnia
Beyond the preview
Go deeper on ACTRN12614001293651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614001293651.